Foghorn Therapeutics to Present at Citizens Life Sciences Conference

Foghorn Therapeutics will participate in the Citizens Life Sciences Conference on May 7-8, 2025, in New York. Management, including President and CEO Adrian Gottschalk, will participate in a fireside chat and one-on-one meetings. Foghorn is a clinical-stage biotechnology company developing medicines to correct abnormal gene expression, with an initial focus on oncology.

Foghorn Therapeutics (NASDAQ: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, has announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO Adrian Gottschalk will present in a fireside chat on May 7 at 9:30 a.m. EST and participate in one-on-one meetings throughout the day. The company's Gene Traffic Control® platform primarily targets oncology applications and aims to develop treatments for a broad spectrum of diseases.

Foghorn Therapeutics, founded in 2015, is pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression. The company uses its proprietary Gene Traffic Control platform to systematically study, identify, and validate potential drug targets within the chromatin regulatory system. Key programs include FHD-286, a small molecule inhibitor for metastatic uveal melanoma and relapsed/refractory acute myeloid leukemia, and FHD-609, a small molecule protein degrader for synovial sarcoma.

Management will provide insights into the company's pipeline and recent preclinical data during the conference. This includes updates on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909, and its selective CBP and EP300 degrader programs. The company has also been actively involved in research collaborations, including a partnership with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target.

The Citizens Life Sciences Conference is an opportunity for Foghorn Therapeutics to engage with industry experts, investors, and potential partners. CEO Adrian Gottschalk's fireside chat and one-on-one meetings will offer valuable insights into the company's strategic direction and pipeline of potential first-in-class medicines.

For more information on Foghorn Therapeutics, visit their website at [www.foghorntx.com](http://www.foghorntx.com).

References:
[1] https://www.stocktitan.net/news/FHTX/foghorn-therapeutics-to-participate-in-the-citizens-life-sciences-8wz7upxouwg1.html
[2] https://quantisnow.com/company/FHTX